HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Emiliano Calvo Selected Research

Squamous Cell Carcinoma of Head and Neck

2/2022First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
1/2021Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
1/2021Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Emiliano Calvo Research Topics

Disease

80Neoplasms (Cancer)
04/2024 - 09/2002
14Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2022 - 01/2003
13Renal Cell Carcinoma (Grawitz Tumor)
04/2022 - 03/2009
11Disease Progression
11/2023 - 06/2013
7Colorectal Neoplasms (Colorectal Cancer)
05/2024 - 01/2002
7Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2021 - 07/2016
6Fatigue
01/2022 - 01/2016
5Nausea
01/2022 - 01/2016
5Carcinoma (Carcinomatosis)
11/2019 - 11/2016
4Melanoma (Melanoma, Malignant)
03/2024 - 08/2014
4Breast Neoplasms (Breast Cancer)
10/2023 - 11/2002
4Exanthema (Rash)
01/2021 - 05/2009
4Neutropenia
01/2021 - 04/2008
3Pancreatic Neoplasms (Pancreatic Cancer)
09/2023 - 01/2017
3Endometrial Neoplasms (Endometrial Cancer)
09/2023 - 11/2021
3Squamous Cell Carcinoma of Head and Neck
02/2022 - 01/2021
3Vomiting
01/2021 - 11/2016
3Neoplasm Metastasis (Metastasis)
03/2015 - 03/2009
2Prostatic Neoplasms (Prostate Cancer)
02/2024 - 06/2009
2Pruritus (Itching)
01/2023 - 01/2021
2Headache (Headaches)
01/2021 - 05/2009
2Triple Negative Breast Neoplasms
01/2021 - 08/2014
2Adenocarcinoma
10/2020 - 01/2019
2Hypertension (High Blood Pressure)
10/2020 - 05/2009
2Lung Neoplasms (Lung Cancer)
01/2018 - 12/2004
2Febrile Neutropenia
01/2017 - 03/2015
2Pneumonia (Pneumonitis)
07/2016 - 08/2010
2Anemia
06/2015 - 03/2015
2Glioma (Gliomas)
04/2015 - 02/2015
2Stomatitis
03/2015 - 04/2008
2Hyperglycemia
10/2011 - 04/2008
1Vaccinia
03/2024

Drug/Important Bio-Agent (IBA)

10Proteins (Proteins, Gene)FDA Link
02/2024 - 12/2004
9NivolumabIBA
01/2020 - 07/2016
7LigandsIBA
02/2022 - 03/2005
7Phosphotransferases (Kinase)IBA
01/2021 - 02/2009
7EverolimusFDA Link
11/2020 - 04/2008
7GemcitabineFDA Link
12/2018 - 01/2003
6PM 01183IBA
04/2024 - 01/2017
6Immune Checkpoint InhibitorsIBA
06/2023 - 01/2018
6Monoclonal AntibodiesIBA
01/2023 - 03/2005
6Cisplatin (Platino)FDA LinkGeneric
01/2021 - 01/2003
6IpilimumabIBA
01/2020 - 07/2016
5PlatinumIBA
01/2021 - 07/2016
5TOR Serine-Threonine KinasesIBA
11/2020 - 04/2008
5Sunitinib (Sutent)FDA Link
11/2020 - 10/2008
4atezolizumabIBA
05/2024 - 01/2019
4pembrolizumabIBA
03/2024 - 12/2018
4B7-H1 AntigenIBA
10/2023 - 10/2018
4ErbB Receptors (EGF Receptor)IBA
06/2023 - 12/2004
4Biomarkers (Surrogate Marker)IBA
01/2021 - 04/2015
4Dihydrotachysterol (AT 10)IBA
01/2019 - 04/2008
4LY2603618IBA
01/2017 - 10/2014
3AntigensIBA
12/2023 - 01/2021
3Immunoconjugates (Immunoconjugate)IBA
10/2023 - 10/2020
3AntibodiesIBA
06/2023 - 03/2015
3Bevacizumab (Avastin)FDA Link
12/2022 - 05/2009
3Paclitaxel (Taxol)FDA LinkGeneric
12/2022 - 01/2003
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2022 - 06/2015
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2021 - 12/2004
3LY-2157299IBA
01/2021 - 02/2015
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
11/2020 - 02/2009
3RamucirumabIBA
10/2020 - 12/2018
3Cetuximab (Erbitux)FDA Link
09/2019 - 03/2005
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2019 - 05/2009
3Docetaxel (Taxotere)FDA Link
03/2015 - 11/2002
3Tyrosine Kinase InhibitorsIBA
05/2014 - 09/2002
3Erlotinib Hydrochloride (CP 358,774)FDA Link
05/2013 - 05/2006
3Sorafenib (BAY 43-9006)FDA Link
07/2012 - 02/2009
3Imatinib Mesylate (Gleevec)FDA Link
02/2009 - 09/2002
3Vinorelbine (Navelbine)FDA LinkGeneric
06/2004 - 11/2002
2Hormones (Hormone)IBA
10/2023 - 06/2009
2budigalimabIBA
02/2022 - 01/2021
2Alanine Transaminase (SGPT)IBA
01/2022 - 06/2015
2Doxorubicin (Adriamycin)FDA LinkGeneric
11/2021 - 10/2021
2Transforming Growth Factor beta (TGF-beta)IBA
01/2021 - 04/2015
2Antineoplastic Agents (Antineoplastics)IBA
01/2019 - 02/2009
2Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2019 - 10/2015
2erdafitinibIBA
01/2019 - 10/2015
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2018 - 08/2014
2Checkpoint Kinase 1IBA
01/2017 - 01/2017
2Pemetrexed (MTA)FDA Link
01/2017 - 10/2014
2Axitinib (AG 013736)IBA
10/2015 - 05/2014
2Transforming Growth Factors (Transforming Growth Factor)IBA
04/2015 - 02/2015
2temsirolimusFDA Link
03/2013 - 02/2009
2Oxaliplatin (Eloxatin)FDA LinkGeneric
08/2002 - 01/2002
2Irinotecan (Camptosar)FDA LinkGeneric
08/2002 - 01/2002
2Fluorouracil (Carac)FDA LinkGeneric
08/2002 - 01/2002
1cibisatamabIBA
05/2024
1Itraconazole (Sporanox)FDA LinkGeneric
04/2024
1Cytochrome P-450 CYP3A InhibitorsIBA
04/2024
1VaccinesIBA
03/2024
1Kallikreins (Kallikrein)IBA
02/2024
1Bosentan (Tracleer)FDA Link
01/2024

Therapy/Procedure

34Therapeutics
04/2024 - 01/2003
9Drug Therapy (Chemotherapy)
01/2020 - 11/2002
5Immunotherapy
01/2023 - 01/2020
3Radiotherapy
01/2021 - 03/2009
2TP protocol
06/2004 - 01/2003
2Combination Drug Therapy (Combination Chemotherapy)
06/2004 - 08/2002